NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE217893 Query DataSets for GSE217893
Status Public on Oct 02, 2023
Title GM-CSF-activated STAT5A but not STAT5B regulates macrophage functions and inflammation in atherosclerosis
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Inhibition of STAT5 was recently reported to reduce mouse atherosclerosis. However, the regulatory role of STAT5 isoforms STAT5A and STAT5B in human disease and more specifically in macrophages remains unknown. Here, we demonstrate reciprocal expression regulation of STAT5A and B in human atherosclerotic lesions. The former was highly upregulated in ruptured over stable plaque and correlated with macrophage presence, a finding that was corroborated by the high chromosomal accessibility of STAT5A but not B gene in plaque macrophages. Phosphorylated STAT5 correlated with macrophages confirming its activation status. As macrophage STAT5 is activated by GM-CSF, we studied the effects of its silencing in GM-CSF differentiated human macrophages. STAT5A knockdown blunted NF-kB pathway, phagocytosis, cholesterol metabolism, and apoptosis terms. These changes at transcriptional level could be confirmed at functional level, with significant increases in apoptosis and phagocytosis and decreases in lipid uptake and IL-6, IL8, and TNFa cytokine secretion after STAT5A knockdown. Finally, inhibition of general and isoform A specific STAT5 inhibitor significantly reduced the secretion of TNFa, IL-8 and IL-10 in ex vivo tissue slices of advanced human atherosclerotic plaques. In summary, we identify STAT5A as important determinant of macrophage functions and inflammation in the context of atherosclerosis and show its promise as therapeutic target for human atherosclerotic plaque inflammation.
 
Overall design Gene expression profiling using RNA-Seq. Human monocytes differentiated into macrophages with GM-CSF for 7 days and subsequent treatment with siRNA for 24h and an additional 24h resting period.
 
Contributor(s) Nagenborg J, Ruder A, Jin H, Mees B, Temmerman L, Donner M, Goossens P, Biessen E
Citation(s) 37920458
Submission date Nov 14, 2022
Last update date Nov 16, 2023
Contact name Han Jin
E-mail(s) han.jin@scilifelab.se
Organization name Science for Life Laboratory
Street address Tomtebodavägen 23
City Solna
ZIP/Postal code 17165
Country Sweden
 
Platforms (1)
GPL30173 NextSeq 2000 (Homo sapiens)
Samples (9)
GSM6729516 GM, siCtr (Rep 1)
GSM6729517 GM, siCtr (Rep 2)
GSM6729518 GM, siCtr (Rep 3)
Relations
BioProject PRJNA901347

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE217893_exp_counts.tsv.gz 266.2 Kb (ftp)(http) TSV
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap